DE60334068D1 - VERFAHREN ZUR HERSTELLUNG EINER AMORPHEN FORM DES HEMICALCIUMSALZES VON (3R, 5R)-7-c3-PHENYL-4-PHENYL CARBAMOYL-2-(4-FLUORPHENYL)-5-ISOPROPYL PYRROL-1-YLÜ-3,5-DIHYDROXY HEPTAN SÄURE (ATORVASTATIN) - Google Patents

VERFAHREN ZUR HERSTELLUNG EINER AMORPHEN FORM DES HEMICALCIUMSALZES VON (3R, 5R)-7-c3-PHENYL-4-PHENYL CARBAMOYL-2-(4-FLUORPHENYL)-5-ISOPROPYL PYRROL-1-YLÜ-3,5-DIHYDROXY HEPTAN SÄURE (ATORVASTATIN)

Info

Publication number
DE60334068D1
DE60334068D1 DE60334068T DE60334068T DE60334068D1 DE 60334068 D1 DE60334068 D1 DE 60334068D1 DE 60334068 T DE60334068 T DE 60334068T DE 60334068 T DE60334068 T DE 60334068T DE 60334068 D1 DE60334068 D1 DE 60334068D1
Authority
DE
Germany
Prior art keywords
sub
phenyl
pyrrol
isopropyl
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60334068T
Other languages
German (de)
English (en)
Inventor
Stanislav Radl
Jan Stach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Application granted granted Critical
Publication of DE60334068D1 publication Critical patent/DE60334068D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04—Calcium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60334068T 2002-02-01 2003-01-30 VERFAHREN ZUR HERSTELLUNG EINER AMORPHEN FORM DES HEMICALCIUMSALZES VON (3R, 5R)-7-c3-PHENYL-4-PHENYL CARBAMOYL-2-(4-FLUORPHENYL)-5-ISOPROPYL PYRROL-1-YLÜ-3,5-DIHYDROXY HEPTAN SÄURE (ATORVASTATIN) Expired - Lifetime DE60334068D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20020413A CZ296967B6 (cs) 2002-02-01 2002-02-01 Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
PCT/CZ2003/000007 WO2003068739A1 (en) 2002-02-01 2003-01-30 Method of manufacturing an amorphous form of the hemi-calcium salt of (3r, 5r) 7- 3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)

Publications (1)

Publication Number Publication Date
DE60334068D1 true DE60334068D1 (de) 2010-10-21

Family

ID=27674298

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60334068T Expired - Lifetime DE60334068D1 (de) 2002-02-01 2003-01-30 VERFAHREN ZUR HERSTELLUNG EINER AMORPHEN FORM DES HEMICALCIUMSALZES VON (3R, 5R)-7-c3-PHENYL-4-PHENYL CARBAMOYL-2-(4-FLUORPHENYL)-5-ISOPROPYL PYRROL-1-YLÜ-3,5-DIHYDROXY HEPTAN SÄURE (ATORVASTATIN)

Country Status (15)

Country Link
US (1) US7208608B2 (https=)
EP (1) EP1470106B1 (https=)
JP (1) JP2005521685A (https=)
KR (1) KR20040081172A (https=)
AT (1) ATE480516T1 (https=)
AU (1) AU2003213986A1 (https=)
CZ (1) CZ296967B6 (https=)
DE (1) DE60334068D1 (https=)
EA (1) EA007432B1 (https=)
ES (1) ES2347324T3 (https=)
HU (1) HUP0402590A3 (https=)
PL (1) PL209756B1 (https=)
PT (1) PT1470106E (https=)
UA (1) UA76826C2 (https=)
WO (1) WO2003068739A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520740C (en) * 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
AU2003247327A1 (en) * 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
ATE545629T1 (de) * 2004-03-17 2012-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von atorvastatin- calcium in amorpher form
US8044086B2 (en) * 2004-07-16 2011-10-25 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
US7645888B2 (en) 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
CA2582087A1 (en) * 2004-10-18 2006-04-27 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
WO2006048893A2 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited A process for synthesis of large particle size statin compounds
CA2499047A1 (en) 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
GB2424880A (en) * 2005-04-06 2006-10-11 Generics Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
WO2007020413A1 (en) 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
AU2006281237A1 (en) 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2009139730A1 (en) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Preparation of novel non-crystalline forms of atorvastatin calcium
KR101050722B1 (ko) * 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
EP2327682A1 (en) * 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2010069593A1 (en) * 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
US20130041162A1 (en) * 2010-04-19 2013-02-14 Dsm Sinochem Pharmaceuticals Netherlands B.V. Production of atorvastatin low in ether impurities
CN108774164A (zh) * 2018-05-29 2018-11-09 宣城美诺华药业有限公司 一种阿托伐他汀钙合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI0848704T1 (en) * 1995-07-17 2002-04-30 Warner-Lambert Company Form iii crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
KR100389518B1 (ko) * 1995-07-17 2003-11-15 워너-램버트 캄파니 엘엘씨 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
IN191236B (https=) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
IN190564B (https=) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
WO2003018547A2 (en) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)

Also Published As

Publication number Publication date
PL209756B1 (pl) 2011-10-31
EP1470106B1 (en) 2010-09-08
CZ296967B6 (cs) 2006-08-16
US7208608B2 (en) 2007-04-24
EP1470106A1 (en) 2004-10-27
PT1470106E (pt) 2010-09-23
US20050131055A1 (en) 2005-06-16
UA76826C2 (uk) 2006-09-15
KR20040081172A (ko) 2004-09-20
JP2005521685A (ja) 2005-07-21
ES2347324T3 (es) 2010-10-28
WO2003068739A1 (en) 2003-08-21
HUP0402590A2 (hu) 2005-03-29
HUP0402590A3 (en) 2010-06-28
EA200400977A1 (ru) 2004-12-30
PL370495A1 (en) 2005-05-30
EA007432B1 (ru) 2006-10-27
CZ2002413A3 (cs) 2003-10-15
ATE480516T1 (de) 2010-09-15
AU2003213986A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
DE60334068D1 (de) VERFAHREN ZUR HERSTELLUNG EINER AMORPHEN FORM DES HEMICALCIUMSALZES VON (3R, 5R)-7-c3-PHENYL-4-PHENYL CARBAMOYL-2-(4-FLUORPHENYL)-5-ISOPROPYL PYRROL-1-YLÜ-3,5-DIHYDROXY HEPTAN SÄURE (ATORVASTATIN)
DE60012045D1 (de) Verfahren zur herstellung von amorphem atorvastatin
EE03194B1 (et) Ühendid, nende kasutamine magustavate toimeainetena ja nende valmistamise meetod
BRPI0411366A (pt) derivados de indazolil (indolil) maleimida substituìdos como inibidores de cinase
JP2005521685A5 (https=)
MX9206679A (es) Nuevo proceso para la preparacion de derivados substituidos de la tiazolidindiona
EP1429771A4 (en) BICYCLIC COMPOUNDS AS AN INHIBITORS OF CHEMOKIN BINDING AT US28
EA200200719A1 (ru) Способ получения циталопрама
NO20062656L (no) Fremgangsmate for fremstilling av statiner
DE69911430D1 (de) Verfahren zur herstellung von 1-(1h)-benzoquinolizin-3-on derivaten
WO2020016903A1 (en) An improved and commercially viable process for preparation of pyrrole derivatives with improved impurity profile & minimisation of unit operations.
DE69521012D1 (de) Verfahren zur Herstellung von 1-(4,5-Dihydro)2-thiazolyl-3-Azetidinthiolderivaten
EA200501734A1 (ru) Способ получения (4-гидрокси-6-оксотетрагидропиран-2-ил)ацетонитрила и его производных
HRP20100290T1 (hr) Postupak priprave rosuvastatina i intermedijera
US20060084816A1 (en) Process for the production of atorvastatin calcium
ATE394393T1 (de) Neue polymorphe formen eines 1-pyrrol-derivates, zwischenprodukt zur herstellung von atorvastatin
EA200200641A1 (ru) Кальцийдикарбоксилатные эфиры, способы их получения и лечение ими заболевания сосудов и диабета
US7615647B2 (en) Process for producing atorvastatin hemicalcium
HUP9802936A2 (hu) Eljárás sztatinok előállítására laktonképzéssel
FI20030026A0 (fi) Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita
ATE155134T1 (de) Verfarhen zur herstellung von alpha-aryl-gamma- butyrolactonen
ATE117977T1 (de) Verfahren zur herstellung von alpha-beta- ungesättigten ketonen.
CN104619684A (zh) 生产阿托伐他汀中间体的方法
AU4414297A (en) Method of preparing phosphodiesterase iv inhibitors
WO2025184448A3 (en) Methods and intermediates for preparing therapeutic compounds